Acquisition by Matthew Foehr of 225000 shares of OmniAb at 5.19 subject to Rule 16b-3
OABI Stock | USD 3.52 0.07 1.95% |
Under 68% of OmniAb's investor base is looking to short. The analysis of the overall investor sentiment regarding OmniAb Inc suggests that many traders are alarmed. OmniAb's investing sentiment shows overall attitude of investors towards OmniAb Inc.
OmniAb |
Filed transaction by OmniAb Inc Director, Officer: President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at news.google.com
![]() |
OmniAb Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards OmniAb can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OmniAb Fundamental Analysis
We analyze OmniAb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OmniAb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OmniAb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
OmniAb is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
OmniAb Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OmniAb stock to make a market-neutral strategy. Peer analysis of OmniAb could also be used in its relative valuation, which is a method of valuing OmniAb by comparing valuation metrics with similar companies.
Peers
OmniAb Related Equities
EWTX | Edgewise Therapeutics | 1.95 | ||||
VRNA | Verona Pharma | 1.81 | ||||
PMVP | Pmv Pharmaceuticals | 1.42 | ||||
ITOS | Iteos Therapeutics | 1.29 | ||||
ACET | Adicet Bio | 1.12 | ||||
KROS | Keros Therapeutics | 0.27 | ||||
IDYA | Ideaya Biosciences | 0.48 | ||||
ERAS | Erasca | 0.71 | ||||
IPSC | Century Therapeutics | 0.93 | ||||
GLUE | Monte Rosa | 1.03 | ||||
OLMA | Olema Pharmaceuticals | 1.29 | ||||
CGEM | Cullinan Oncology | 1.29 | ||||
LEGN | Legend Biotech | 1.30 | ||||
IKNA | Ikena Oncology | 2.14 | ||||
VOR | Vor Biopharma | 3.17 | ||||
PASG | Passage Bio | 3.77 | ||||
BCAB | Bioatla | 10.53 |
Complementary Tools for OmniAb Stock analysis
When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |